The letter by Yuan et al summarised six large retrospective cohort studies comparing the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) who received tenofovir disoproxil fumarate (TDF) or entecavir monotherapy. 1 Their meta-analysis suggested that TDF-treated patients had a lower HCC occurrence rate than entecavir-treated patients before or after propensity score matching. Most studies were from Asia (mainly Korea). All studies performed propensity score analysis to handle confounding bias.
tium that encompassed 19 centres from six countries or regions (United States, n = 5; China, n = 3; Hong Kong, n = 2; Japan, n = 4; South Korea, n = 1; Taiwan, n = 4). 5 Therefore, most of the participants were of Asian origin. All these six retrospective cohort studies composed of treatment-naïve CHB patients treated with either TDF or entecavir monotherapy. [3] [4] [5] [6] [7] [8] The follow-up duration ranged from 32.0 to 69.9 months. The overall incidence rate of HCC was 3.20% (581/18157) in TDF group and 5.24% (2523/48130) in entecavir group. Subgroup analysis in propensity score matching analysis found that the incidence rate of HCC was 3.35% (524/15645) and 5.40% (845/15645) in the corresponding groups. Pooled results revealed that CHB patients treated with TDF monotherapy showed a statistically significant lower rate of HCC occurrence compared to entecavir monotherapy as a whole (RR 0.46, 95% CI 0.33-0.66, P < 0.001) or after propensity score matching analysis (RR 0.53, 95% CI 0.36-0.76, P < 0.001). The results were consistent with that of sensitivity analyses based on the fixed-effect or random-effect model, or excluded one study one by one.
In conclusion, this meta-analysis revealed that TDF was superior to entecavir monotherapy for HCC prevention in CHB.
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